PDCD1 and melanoma: A study in humans showed that T-VEC with anti–PD-1 immunotherapy in melanoma had a tolerable safety profile, and the combination appeared to have greater efficacy against melanoma than T-VEC or checkpoint blockade monotherapy (81).